| Literature DB >> 28196595 |
Jun Li1, Wei Zhao2, Rehan Akbani1, Wenbin Liu1, Zhenlin Ju1, Shiyun Ling1, Christopher P Vellano2, Paul Roebuck1, Qinghua Yu2, A Karina Eterovic2, Lauren A Byers3, Michael A Davies4, Wanleng Deng5, Y N Vashisht Gopal5, Guo Chen5, Erika M von Euw6, Dennis Slamon6, Dylan Conklin6, John V Heymach7, Adi F Gazdar8, John D Minna8, Jeffrey N Myers9, Yiling Lu2, Gordon B Mills10, Han Liang11.
Abstract
Cancer cell lines are major model systems for mechanistic investigation and drug development. However, protein expression data linked to high-quality DNA, RNA, and drug-screening data have not been available across a large number of cancer cell lines. Using reverse-phase protein arrays, we measured expression levels of ∼230 key cancer-related proteins in >650 independent cell lines, many of which have publically available genomic, transcriptomic, and drug-screening data. Our dataset recapitulates the effects of mutated pathways on protein expression observed in patient samples, and demonstrates that proteins and particularly phosphoproteins provide information for predicting drug sensitivity that is not available from the corresponding mRNAs. We also developed a user-friendly bioinformatic resource, MCLP, to help serve the biomedical research community.Entities:
Keywords: biomarker; cancer cell lines; data portal; drug sensitivity; proteomics; reverse-phase protein array; signaling pathways
Mesh：
Substances：
Year: 2017 PMID： 28196595 PMCID： PMC5501076 DOI： 10.1016/j.ccell.2017.01.005
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743